» Articles » PMID: 7690772

Impaired Interferon Production and Natural Killer Cell Activation in Patients with the Skin Cancer-prone Disorder, Xeroderma Pigmentosum

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1993 Sep 1
PMID 7690772
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder with sun sensitivity, markedly increased skin cancer susceptibility, and defective DNA repair without consistently identified symptoms of immune deficiency. We examined natural killer (NK) cell activity and interferon production in peripheral blood lymphocytes (PBL) of eight XP patients who had multiple primary skin cancers. The XP patients had normal numbers of T cells and NK cells, as well as normal lymphokine-activated killer cell activity and normal tumor necrosis factor-alpha production. Unstimulated NK cell function was 40% of normal controls in five XP patients, but was normal in three other XP patients. However, PBL from all the XP patients tested showed no enhancement of NK activity by the interferon inducer, polyinosinic acid:polycytidilic acid (polyIC) but enhancement by interferon-alpha was normal, suggesting an impairment in interferon production. Parallel studies in non-XP skin cancer patients revealed that both unstimulated and polyIC-enhanced NK activity were normal. Further investigation using PBL from XP patients revealed that the production of interferon-gamma after stimulation with interferon inducers (polyIC, interleukin 2, or K562 tumor cells) was 13-43% of normals. These data indicate that XP lymphocytes have a defect in production of interferons and suggest that defective interferon production, as well as DNA repair defects, may play an important role in the susceptibility of XP patients to skin cancer.

Citing Articles

Inflammatory landscape in Xeroderma pigmentosum patients with cutaneous melanoma.

Chikhaoui A, Jones M, Rezen T, Ben Ahmed M, Naouali C, Komel R Sci Rep. 2022; 12(1):13854.

PMID: 35974070 PMC: 9381529. DOI: 10.1038/s41598-022-17928-z.


Human Variation in DNA Repair, Immune Function, and Cancer Risk.

Cheong A, Nagel Z Front Immunol. 2022; 13:899574.

PMID: 35935942 PMC: 9354717. DOI: 10.3389/fimmu.2022.899574.


Type I Interferon Induction in Cutaneous DNA Damage Syndromes.

Klein B, Gunther C Front Immunol. 2021; 12:715723.

PMID: 34381458 PMC: 8351592. DOI: 10.3389/fimmu.2021.715723.


Cytotoxicity and Mutagenicity of Narrowband UVB to Mammalian Cells.

Buglewicz D, Mussallem J, Haskins A, Su C, Maeda J, Kato T Genes (Basel). 2020; 11(6).

PMID: 32545288 PMC: 7349664. DOI: 10.3390/genes11060646.


Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.

Elinoff J, Chen L, Dougherty E, Awad K, Wang S, Biancotto A Cardiovasc Res. 2017; 114(1):65-76.

PMID: 29036418 PMC: 5852512. DOI: 10.1093/cvr/cvx198.


References
1.
Kawase I, Urdal D, Brooks C, Henney C . Selective depletion of NK cell activity in vivo and its effect on the growth of NK-sensitive and NK-resistant tumor cell variants. Int J Cancer. 1982; 29(5):567-74. DOI: 10.1002/ijc.2910290513. View

2.
Pollack S, Hallenbeck L . In vivo reduction of NK activity with anti-NK 1 serum: direct evaluation of NK cells in tumor clearance. Int J Cancer. 1982; 29(2):203-7. DOI: 10.1002/ijc.2910290215. View

3.
Abb J, Abb H, Deinhardt F . Retinoic acid suppression of human leukocyte interferon production. Immunopharmacology. 1982; 4(4):303-10. DOI: 10.1016/0162-3109(82)90051-0. View

4.
Ortaldo J, Mantovani A, Hobbs D, Rubinstein M, Pestka S, Herberman R . Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int J Cancer. 1983; 31(3):285-9. DOI: 10.1002/ijc.2910310306. View

5.
Rhodes J . Human interferon action: reciprocal regulation by retinoic acid and beta-carotene. J Natl Cancer Inst. 1983; 70(5):833-7. View